Discovery of a Potent, Orally Available, and Isoform-Selective Retinoic Acid β2 Receptor Agonist

Birgitte W. Lund, Fabrice Piu, Natalie K. Gauthier, Anne Eeg, Erika A. Currier, Vladimir Sherbukhin, Mark R. Brann, Uli Hacksell, Roger Olsson

Journal of Medicinal Chemistry · 2005 · 65 citations · 9 references

DOIFull text

Open access

Concepts

Abstract

4'-Octyl-4-biphenylcarboxylic acid (1g, AC-55649) was identified as a highly isoform-selective agonist at the human RARbeta2 receptor in a functional intact cell-based screening assay. The subsequent hit to lead optimization transformed the lipophilic, poorly soluble hit into a more potent and orally available compound (2, AC-261066) with retained beta2 selectivity and greatly improved physiochemical properties. Being an isoform-selective RARbeta2 receptor agonist that discriminates between nuclear receptor isoforms having identical ligand binding domains, 2 will be useful as a pharmacological research tool but also a valuable starting point for drug development.

References

9